Apnimed is a pharmaceutical company focused on developing treatments for obstructive sleep apnea (OSA).

Apnimed

Apnimed is a clinical-stage company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders.

Tao Capital Partners

Morningside Venture Investments

Morningside Ventures

Columbia Seligman Investments

Sectoral Asset Management

Alpha Wave Global

Alpha Wave Ventures

In the United States alone, more than 36 million people living with obstructive sleep apnea (OSA) remain undiagnosed and untreated.  
 
To help spread awareness of OSA symptoms, Project Sleep is launching its first #SleepApneaSquad broadcast, led by sleep apnea advocates and experts. 
 
Tune into the live broadcast on YouTube today at 2 p.m. ET: https://bit.ly/3yvUaAL

Did you know that there is a connection between Type 2 diabetes and obstructive sleep apnea? 80% of people with Type 2 diabetes also have sleep apnea. 

Learn more about sleep apnea and related health issues: 🔗 https://lnkd.in/ecw78Yag

Many people living with obstructive sleep apnea (OSA) delay seeking out diagnosis and treatment for a variety of reasons, from lack of awareness to low acceptance of current treatment options, with at least 80% of people with OSA remaining undiagnosed. 
  
To address this concerning public health gap, Project Sleep has launched the #SleepApneaSquad, a new educational initiative backed by leading clinicians and advocates to help people navigate the complex OSA journey.  

We’re thrilled to support this much needed program which will help support unmet needs in the OSA community. Learn more: https://prn.to/46puNwU

We’re thrilled to share Michele Miller, PharmD has joined our team as Director, Medical Information. With over a decade of experience in the field, Michele will play a key role in elevating relationships with health care personnel and the patient experience while building a best-in-industry Medical Information capability at Apnimed. Welcome, Michele!

Interested in working with us? Explore more Apnimed careers. https://bit.ly/4dO72Bt

Sleep apnea is a common but serious sleep disorder. The disorder is caused by repetitive periods when airflow is interrupted during sleep due to a narrowing or closure to the throat. A complete blockage of airflow is an apnea, and a partial interruption is a hypopnea. Each apnea or hypopnea can result in drops in oxygen levels and brief awakenings or sleep disturbances.

Continue learning: https://lnkd.in/ecw78Yag

Typical symptoms of sleep apnea are snoring, snorting, or gasping during sleep, unrefreshed sleep, and daytime sleepiness. These multiple breathing interruptions may prevent you from sleeping well, leaving you feeling extra tired during the day.

Continue learning: 🔗 https://lnkd.in/ecw78Yag

msh id	COM:APNIMED
symbol	-
name	Apnimed
homepage url	https://apnimed.com
country	US
sector	Healthcare & Health Services
industry	Pharmaceuticals
market	PRIVATE
employee count	69
crunchbase url	-
linkedin url	https://www.linkedin.com/company/apnimed
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

APNI

COM:APNIMED

Apnimed

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-